Using VEGF TKIs to modulate the immunosuppressive microenvironment and increase the efficacy of ICIs is another strategy that has been tested as a first-line treatment of HCC; however, the studies evaluating these combinations have shown mixed results. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.